"Loss of Heterozygosity" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.
| Descriptor ID |
D019656
|
| MeSH Number(s) |
G05.365.590.029.530
|
| Concept/Terms |
Loss of Heterozygosity- Loss of Heterozygosity
- Heterozygosity Loss
- Allelic Loss
- Allelic Losses
- Heterozygosity, Loss of
|
Below are MeSH descriptors whose meaning is more general than "Loss of Heterozygosity".
Below are MeSH descriptors whose meaning is more specific than "Loss of Heterozygosity".
This graph shows the total number of publications written about "Loss of Heterozygosity" by people in this website by year, and whether "Loss of Heterozygosity" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1997 | 0 | 8 | 8 |
| 1998 | 13 | 23 | 36 |
| 1999 | 13 | 27 | 40 |
| 2000 | 10 | 28 | 38 |
| 2001 | 15 | 22 | 37 |
| 2002 | 7 | 16 | 23 |
| 2003 | 10 | 15 | 25 |
| 2004 | 8 | 13 | 21 |
| 2005 | 11 | 15 | 26 |
| 2006 | 3 | 15 | 18 |
| 2007 | 5 | 11 | 16 |
| 2008 | 5 | 9 | 14 |
| 2009 | 3 | 12 | 15 |
| 2010 | 1 | 5 | 6 |
| 2011 | 2 | 8 | 10 |
| 2012 | 3 | 8 | 11 |
| 2013 | 3 | 5 | 8 |
| 2014 | 0 | 4 | 4 |
| 2015 | 3 | 2 | 5 |
| 2016 | 1 | 6 | 7 |
| 2017 | 0 | 4 | 4 |
| 2018 | 2 | 4 | 6 |
| 2019 | 1 | 3 | 4 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 7 | 8 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Loss of Heterozygosity" by people in Profiles.
-
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status. Breast Cancer. 2024 Sep; 31(5):886-897.
-
Determinants of mosaic chromosomal alteration fitness. Nat Commun. 2024 May 07; 15(1):3800.
-
Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children's Oncology Group Studies AREN03B2 and AREN0532. Cancer. 2024 03 01; 130(5):792-802.
-
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 02; 164(2):245-253.
-
Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nat Commun. 2021 11 17; 12(1):6655.
-
Assessing Prevalence and Carrier Frequency of Succinic Semialdehyde Dehydrogenase Deficiency. J Child Neurol. 2021 11; 36(13-14):1218-1222.
-
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. Gynecol Oncol. 2021 12; 163(3):490-497.
-
Bi-allelic loss-of-function variants in BCAS3 cause a syndromic neurodevelopmental disorder. Am J Hum Genet. 2021 06 03; 108(6):1069-1082.
-
Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident. Science. 2021 05 14; 372(6543).
-
Breast tumours maintain a reservoir of subclonal diversity during expansion. Nature. 2021 04; 592(7853):302-308.